{
    "organizations": [],
    "uuid": "0dcd15b50ab73061c75ad7387c4cb1144b5a981e",
    "author": "",
    "url": "https://www.reuters.com/article/brief-vistagen-therapeutics-prepares-to/brief-vistagen-therapeutics-prepares-to-initiate-its-phase-2-study-of-av-101-for-major-depressive-disorder-idUSFWN1PO19A",
    "ord_in_thread": 0,
    "title": "BRIEF-Vistagen Therapeutics ‍Prepares To Initiate Its Phase 2 Study Of Av-101 For Major Depressive Disorder​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 29 (Reuters) - Vistagen Therapeutics Inc:\n* VISTAGEN THERAPEUTICS INC - ‍PREPARES TO INITIATE ITS PHASE 2 STUDY OF AV-101 FOR MAJOR DEPRESSIVE DISORDER​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-30T00:47:00.000+02:00",
    "crawled": "2018-01-30T01:04:50.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "vistagen",
        "therapeutic",
        "inc",
        "vistagen",
        "therapeutic",
        "inc",
        "initiate",
        "phase",
        "study",
        "major",
        "depressive",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}